Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment

  title={Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment},
  author={Adam Fleisher and B. Brooke Sowell and C. Taylor and Anthony Collins Gamst and Ronald C. Petersen and Leon Thal},
  pages={1588 - 1595}
Objective: To investigate the neurocognitive measures that best predict progression from amnestic mild cognitive impairment (aMCI) to Alzheimer disease (AD). Methods: We evaluated 539 participants with aMCI from the Alzheimer's Disease Cooperative Study clinical drug trial of donepezil, vitamin E, or placebo. During the study period of 36 months, 212 aMCI participants progressed to AD. Using progression from aMCI to AD within 36 months as the dependent variable, a generalized linear model was… 

Figures and Tables from this paper

Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment

In moderate stages of amnestic mild cognitive impairment, common cognitive tests provide better predictive accuracy than measures of whole brain, ventricular, entorhinal cortex, or hippocampal volumes for assessing progression to Alzheimer disease.

The Importance of Alzheimer Disease Assessment Scale-cognitive Part in Predicting Progress for Amnestic Mild Cognitive Impairment to Alzheimer Disease

ADAS-Cog subscale is a useful and brief cognitive assessment tool to screen aMCI participants converting to AD within 1 year, and shows a good performance in predicting conversion from a MCI to AD.

Word-List Intrusion Errors Predict Progression to Mild Cognitive Impairment

Intrusion errors appear to reflect subtle change and inefficiencies in cognition that precede impairment detected by neuropsychological total scores in those at risk for progression to MCI.

One-year Outcome of Shanghai Mild Cognitive Impairment Cohort Study.

Early detection of AD and potential selection for clinical trial design should utilize the rt.

Detection of early Alzheimer's disease in MCI patients by the combination of MMSE and an episodic memory test

Pr-AD might be distinguished from S-MCI at baseline using the combination of MMSE and CVLT-LDTR, which are relatively brief and may be readily completed in non-specialist clinical settings.

Can Clinical Data Predict Progression to Dementia in Amnestic Mild Cognitive Impairment?

Clinical features alone were insufficient to predict development of dementia, and patients presenting with amnestic MCI insufficient for the diagnosis of dementia are at high risk of developing dementia on follow-up.

Predictors of rate of cognitive decline in patients with amnestic mild cognitive impairment

Identifying potential predictors of rate of decline from amnestic MCI to AD could be clinically meaningful for prognostic purposes, understanding risk and protective factors, as well as guiding future treatments and clinical trials that could aim to target and delay progression among those patients who are vulnerable to more quickly convert to AD.

Neuropsychological predictors of conversion from mild cognitive impairment to Alzheimer's disease.

Results of this review suggest that measures of delayed recall are the best neuropsychological predictors of conversion from MCI to AD; memory tests providing controlled encoding and cued recall are not necessarily better predictors than free recall tests; stringent cut-off points are necessary to increase the specificity of these predictors.

Amnestic Mild Cognitive Impairment and Early Alzheimer's Disease in an Asian Memory Clinic – Evidence for a Clinical Spectrum

Clinical delineation of aMCI allows the differentiation of those likely to progress for better correlation to biomarker development.



Mild cognitive impairment in different functional domains and incident Alzheimer’s disease

Among persons with mild cognitive impairment, episodic memory impairment is associated with a substantial and persistent elevation in risk of developing AD compared to impairment in other cognitive systems.

Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals.

Patients with mild cognitive impairment can be clinically defined, many members of this group progress to Alzheimer's disease, and APOE epsilon 4 allele status appears to be a strong predictor of clinical progression.

Attention and executive control predict Alzheimer disease in late life: results from the Berlin Aging Study (BASE).

  • M. RappF. Reischies
  • Psychology, Medicine
    The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry
  • 2005
Tailored models of attention and executive function in the preclinical phase of AD in old age support theoretical models of neuropsychological processes before AD onset and significantly predicted incident AD over and above age, gender, and education.

Prediction of probable Alzheimer's disease in memory-impaired patients

It is demonstrated that probable AD can be predicted with a high degree of accuracy and with a relatively brief battery of neuropsychological tests.

Neuropsychological Prediction of Decline to Dementia in Nondemented Elderly

A subanalysis of the high-risk GDS 3 subgroup indicated that cut scores from the paragraph test distinguished nondecliners from decliners (overall accuracies 87%-91%), implying that this assessment may accurately predict future cognitive status in elderly with mild cognitive impairment.

Diagnostic accuracy of the Preclinical AD Scale (PAS) in cognitively mildly impaired subjects

The Preclinical AD Scale is a useful scale to identify subjects with preclinical AD who will become demented during the next 2 or 5 years and step-wise scoring of the PAS can reduce the number of elaborate or expensive diagnostic procedures considerably.

Executive function deficits in early Alzheimer's disease and their relations with episodic memory.

Development of Cognitive Instruments for Use in Clinical Trials of Antidementia Drugs: Additions to the Alzheimer's Disease Assessment Scale That Broaden Its Scope

The major outcome of this investigation was the identification of some potential addtions to the present ADAS that extend both the cognitive domains and the range of symptom severity covered.

Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials.

Patients with MCI had a predominant memory impairment with relative sparing of other cognitive domains and were intermediate between clinically normal individuals and patients with AD on cognitive and functional ratings.

Preclinical prediction of AD using neuropsychological tests

The specific tests that contributed to these discriminations, in conjunction with recent neuropathological and neuroimaging data from preclinical cases, have implications for which brain regions may be affected during the prodromal phase of AD.